Gilead Sciences (NASDAQ:GILD) and Eisai Co., Ltd. have entered into an agreement for the distribution and co-promotion of filgotinib, an oral, selective JAK1 inhibitor, in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA).
Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. The companies will jointly commercialize the medicine if approved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.